Cost-utility analysis compares implantable tibial neuromodulation with conservative therapy, suggesting improved outcomes for urgency urinary incontinence.
Over 3 years, ITNM with an external wearable battery improves quality-adjusted survival and lowers overall payer costs compared with conservative therapies for UUI, supporting its inclusion as a value-consistent minimally invasive therapy.
No takes yet. Share an insight, caveat, or question.
Amundsen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: